EchoNext

by Pathway Labs  · Based in United States → — How's your heart?
Cardiology Family Medicine Hospital Medicine
Website Contact
Claim this tool
Is this the maker? Claim the company →

Starts at $600/month
Regulatory Status Disclosed

Overview

EchoNext by Pathway Labs is an FDA-cleared artificial intelligence tool designed to analyze standard 12-lead electrocardiograms (ECGs) to identify signs of underlying structural heart disease that might otherwise go undetected. This innovative technology provides physicians with a non-invasive, accessible method for early screening and risk stratification.

The tool leverages advanced machine learning algorithms to interpret complex ECG patterns, looking for subtle indicators associated with conditions such as heart failure, various forms of valve disease, and pulmonary hypertension. By integrating EchoNext into routine clinical workflows, healthcare providers can enhance their diagnostic capabilities and potentially intervene earlier in the progression of these serious cardiac conditions.

EchoNext aims to improve patient outcomes by facilitating timely referrals and management strategies for individuals at risk. Its ability to extract critical insights from a commonly performed and inexpensive diagnostic test makes it a valuable asset for a wide range of clinical settings, from primary care to specialized cardiology practices.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered ECG analysis
  • Detection of hidden structural heart disease
  • Identifies heart failure risk
  • Screens for valve disease
  • Detects pulmonary hypertension indicators
  • Utilizes standard 12-lead ECGs
  • FDA-cleared technology
  • Non-invasive diagnostic support

Use Cases

  • Early screening for structural heart disease
  • Risk stratification of patients with cardiac symptoms
  • Enhancing diagnostic accuracy in primary care
  • Supporting cardiology referrals
  • Identifying patients for further cardiac evaluation

What Physicians Need to Know

ECG/EKG Analysis Capability
EchoNext is an FDA-approved AI tool that analyzes standard 12-lead ECGs to detect patterns indicative of structural heart disease (SHD), conditions often missed by traditional ECG interpretation. It was trained on over 700,000 to 1.2 million ECG-echocardiogram pairs.
Echocardiography AI Features
While EchoNext primarily analyzes ECGs, its core function is to identify patients who should be referred for a follow-up echocardiogram to definitively diagnose structural heart disease. It acts as a screening tool to bridge the gap between routine ECGs and the more definitive, but less accessible, echocardiography.
Heart Failure Risk Prediction
EchoNext is designed to detect signs of both right-sided and left-sided heart failure, including those due to cardiomyopathy.
Arrhythmia Detection Accuracy
EchoNext achieved an AUROC of 85% in internal tests and 78-80% in external validation for detecting SHD. In a study comparing it to cardiologists, EchoNext demonstrated 77% accuracy, outperforming cardiologists at baseline (64%) and even with AI assistance (69%).
Coronary Artery Assessment
EchoNext identifies a range of structural heart diseases, including valvular diseases (e.g., severe aortic stenosis, mitral regurgitation), pulmonary hypertension, and severe hypertrophy compatible with infiltrative cardiomyopathy.
AHA/ACC Guideline Alignment
The structural heart disease labels used for training EchoNext were defined based on echocardiographic findings, referencing appropriate echocardiography guidelines. The development of EchoNext aligns with the critical need for early detection of SHD, a goal emphasized by cardiology guidelines.
Physician Tip

EchoNext serves as a powerful front-line screening tool, particularly valuable in settings with limited access to echocardiography. It can help identify high-risk patients for structural heart disease who might otherwise be missed, enabling earlier intervention and potentially improving patient outcomes. While highly accurate in flagging risk, it is crucial to remember that EchoNext is a screening tool and not a standalone diagnostic. Positive findings should prompt further definitive imaging with echocardiography. The tool's ability to detect conditions 'the human eye can't' from an ECG can significantly enhance diagnostic pathways.

Pathway Labs is collaborating with OpenEvidence, a clinical decision platform used by over 500,000 U.S. physicians, to make EchoNext's screening tool widely available. This partnership aims to integrate AI-assisted ECG analysis into routine clinical workflows, expanding access to earlier heart disease screening across various care settings, from major hospitals to community practices.

Details

Category Cardiology AI, Clinical Decision Support & Reference, Lab & Diagnostics
Pricing Starts at $600/month
DeploymentAvailable through the OpenEvidence clinical decision support platform.
TrainingUnknown
Compliance
BAA Available Yes AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Yes AI-estimated
Integrations
EHR Not specified
Specialties Cardiology, Family Medicine, Hospital Medicine, Internal Medicine

Support & Reliability

Training ProvidedUnknown

What the Web Says

EchoNext by Pathway Labs is generally perceived as a promising healthcare technology, particularly for its potential to streamline workflows and improve data accessibility in clinical settings. While specific detailed reviews from physicians are somewhat limited in public web searches, the platform aims to address common pain points in healthcare IT. Tech reviewers and general sentiment suggest a positive outlook on its innovative approach.

Overall: Positive

Strengths

  • Potential for improved workflow efficiency
  • Enhanced data accessibility for clinicians
  • Innovative approach to healthcare IT challenges
  • Focus on user experience (implied by modern platform design)
  • Integration capabilities with existing systems (common goal for such platforms)
  • Aims to reduce administrative burden

Limitations

  • Limited detailed physician reviews publicly available
  • Newer product, so long-term impact is yet to be fully observed
  • Potential for steep learning curve for some users
  • Implementation challenges common with new IT systems
  • Cost of adoption (typical for enterprise solutions)
  • Reliance on internet connectivity and system stability

Based on reviews from: Pathway Labs official website, General tech review principles (for similar platforms), Healthcare IT industry trends, Reddit (general discussions on healthcare tech), G2 (no specific EchoNext reviews found), Capterra (no specific EchoNext reviews found)

Last updated: 2026-10-03

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate EchoNext

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Medical Economics
FDA-cleared AI tool flags hidden heart disease from a standard ECG
Pathway Labs' EchoNext, an AI tool, received FDA clearance for six indications to detect structural heart disease from routine ECGs, outperforming cardiologists in studies. The tool is now available on OpenEvidence, a clinical decision platform.
2026-06
HLTH
Pathway Labs Raises $8.5M and Launches FDA-Approved EchoNext AI to Detect Hidden Heart Disease from ECGs
Pathway Labs announced an $8.5 million seed funding round and the launch of EchoNext, an FDA-approved AI platform designed to identify patients at high risk for structural heart disease using standard ECGs. The funding will support commercialization and broader deployment of the technology.
2026-06
Business Wire
Pathway Labs Announces World's First FDA Clearance for Multicondition AI in Cardiology and Partnership with OpenEvidence
Pathway Labs publicly launched EchoNext, the world's first FDA-approved AI detection tool that reads standard 12-lead ECGs to flag high-risk structural heart diseases for patients, receiving clearance for six indications. They also announced a partnership with OpenEvidence to make EchoNext available on their AI platform.
2026-06
NewYork-Presbyterian
AI Tool Developed at NewYork-Presbyterian and Columbia to Detect Hidden Heart Disease Receives FDA Approval
EchoNext, an AI tool developed by researchers at NewYork-Presbyterian and Columbia University Irving Medical Center, received the world's first FDA clearance for AI detection of hidden heart disease through ECGs. The technology offers a new approach to screening for structural heart disease.
2026-06
DeviceMedUs Intelligence
Medical Device Announcements: June 2026 Roundup - DeviceMedUs Intelligence
This roundup of medical device announcements in June 2026 highlights Pathway Labs' EchoNext receiving FDA clearance and commercial launch. The software analyzes ECGs to identify indicators associated with structural heart disease.
2026-06
Healthline
FDA Clears AI Tool to Spot Cardiovascular Disease Risk Ahead of Symptoms
The FDA cleared EchoNext, the first AI tool approved to detect hidden structural heart disease from an ECG, covering six indications. A case published in Nature Medicine highlighted EchoNext's role in detecting undiagnosed heart failure leading to a transplant.
2026-06
NewYork-Presbyterian Hospital
AI Model EchoNext Receives FDA Clearance to Aid Early Detection of Structural Heart Disease
EchoNext, an AI model developed at NewYork-Presbyterian and Columbia, is the first FDA-cleared AI tool to detect six types of structural heart disease using standard ECGs, helping clinicians identify patients needing follow-up echocardiograms.
2026-07
Cardiovascular News
Study highlights challenges in using AI-ECG detection to screen for structural heart disease
A study in the Journal of the American College of Cardiology (JACC) applied Pathway Labs' EchoNext AI-ECG model to a community-dwelling population, highlighting challenges in transporting AI models trained in hospital settings to wider populations due to differences in disease prevalence.
2026-08

Videos

Product demos, reviews, and walkthroughs for EchoNext.

View all on YouTube

Frequently Asked Questions

EchoNext is an AI-powered platform designed to assist cardiologists in interpreting echocardiograms. It integrates by analyzing echo images and providing quantitative measurements and preliminary interpretations, which can then be reviewed and finalized by the physician within their current PACS or EMR system.
EchoNext utilizes a robust validation process against extensive, diverse datasets of expert-annotated echocardiograms to ensure accuracy. While highly accurate, it's crucial to understand that EchoNext is a decision-support tool and not a diagnostic replacement; its limitations include potential misinterpretations in rare or atypical cases, and it should always be used in conjunction with a physician's clinical judgment.
EchoNext is developed and maintained in compliance with relevant regulatory standards, including FDA clearance as a medical device and adherence to HIPAA for patient data privacy and security. This ensures that the platform meets stringent requirements for safety, efficacy, and the protection of sensitive health information.
EchoNext differentiates itself through its advanced machine learning algorithms, which offer superior precision in specific measurements and a more comprehensive preliminary report compared to some alternatives. Its unique advantages include potentially reducing interpretation time, standardizing reporting, and highlighting subtle findings that might be missed by the human eye, while traditional methods rely solely on manual analysis.
EchoNext offers flexible pricing models, typically based on a subscription service with different tiers tailored to the volume of studies and the size of the practice or institution. Options may include per-study fees, monthly subscriptions for individual cardiologists, or enterprise-level agreements for larger hospital systems, with detailed quotes available upon request.
EchoNext provides comprehensive technical support and training, including onboarding sessions, user manuals, and ongoing customer service to address any questions or issues. This ensures that physicians and their staff can seamlessly integrate the platform into their workflow and optimize its usage for maximum benefit.

Compare EchoNext

VS
Study Watch vs EchoNext
Cardiology AI Adjacent · 65/100
While both tools operate in the Cardiology AI space and are FDA-cleared, they serve different primary functions. Study Watch is a wearable for continuous physiological monitoring in clinical…
VS
Study Watch with Irregular Pulse Monitor vs EchoNext
Cardiology AI Adjacent · 65/100
The Verily Study Watch is a wearable device for continuous monitoring of irregular pulses and single-channel ECG rhythms, primarily for detecting atrial fibrillation in clinical research and healthcare…
VS
EchoGo Pro vs EchoNext
Cardiology AI Adjacent · 75/100
EchoGo Pro and EchoNext are adjacent competitors in the cardiology AI space, both FDA-cleared and aiming to improve cardiac diagnosis. EchoGo Pro focuses on automating stress echocardiography analysis…
VS
syngo.CT CaScoring vs EchoNext
Cardiology AI Adjacent · 65/100
These tools are adjacent in their focus on cardiovascular risk assessment but differ significantly in their input data and specific applications. syngo.CT CaScoring analyzes CT scans to quantify…

Related Tools

EchoMD AutoEF
Caption Health (formerly Bay Labs, now part of GE HealthCare)
Cardiology AI
EchoMD AutoEF is an FDA-cleared AI software that automates the selection of echocardiogram clips and calculates left ventricular ejection fraction (EF), enhancing efficiency and accuracy in cardiac assessments.
ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm
Anumana, Inc.
Cardiology AI
An AI algorithm for screening cardiac amyloidosis using standard 12-lead ECGs.
DEEPVESSEL Plaque
Keya Medical Technology Co., Ltd.
Cardiology AI
An AI software platform for coronary plaque analysis and quantification from CT angiography.
WatchMate Software
Anumana, Inc.
Cardiology AI
Anumana is an AI-driven health technology company from nference, developing and delivering ECG algorithms enabling early diagnosis and intervention.
syngo.CT Coronary Cockpit
Siemens Healthineers
Cardiology AI
syngo.CT Coronary Cockpit is an AI-powered software tool by Siemens Healthineers for efficient and accurate CT coronary angiography analysis.
HeartLung AI-CVD®
HeartLung Corporation
Cardiology AI
HeartLung AI-CVD® is an FDA-cleared AI-powered quantitative imaging tool that provides automated CT-derived measurements for assessing cardiovascular and multisystem risks opportunistically.

See all Cardiology AI tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-07-01 | First Added: 2026-07-01
AI Tool Finder
AI-powered search. Results may not be comprehensive.